Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PYCR1 antisense RNA 1 (PYCR1-AS1)
- Target
- PYCR1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding transcript, Other (regulatory RNA)
01
Overview
PYCR1 antisense RNA 1 (PYCR1-AS1), also known as RP11-498C9.13, is a long non-coding RNA that functions as an antisense regulator of the PYCR1 gene. It binds to and stabilizes PYCR1 mRNA, preventing its degradation and increasing PYCR1 protein expression. PYCR1-AS1 has been shown to promote tumorigenesis in bladder cancer by enhancing cell proliferation, invasiveness, reactive oxygen species generation, and mitophagy. Downregulation of PYCR1-AS1 inhibits these processes, pointing to its potential as a therapeutic target in oncology. Expression levels of PYCR1-AS1 may have biomarker utility in assessing bladder cancer prognosis. There is evidence that PYCR1-AS1 and related lncRNAs interact with multiple regulatory nodes, though no approved drugs currently target this lncRNA directly.
- Other names
- RP11-498C9.13PYCR1-AS1Long non-coding RNA RP11-498C9.13
02
Mechanism of action
No approved drugs target this RNA; mechanism if targeted would likely involve interference with its RNA-protein or RNA-RNA interactions, or modulating its expression to suppress its function in cancer.
03
Biological functions
Regulation of gene expression (PYCR1 mRNA stability)Promotion of cell proliferationPromotion of cell invasivenessModulation of ROS (reactive oxygen species) generationInduction of mitophagy
04
Disease associations
Cancer (esp. bladder cancer)Possible role in autoimmune disease (Rheumatoid arthritis, based on related transcript RP11-498C9.15)
05
Safety considerations
No direct therapeutic safety concerns are documented, but theoretical concerns would relate to unintended interference with normal gene regulation if targeted.
06
Biomarkers
Expression level of PYCR1-AS1 (RP11-498C9.13) in tumor tissue may serve as a biomarker for poor prognosis in bladder cancerPYCR1 protein expression (stabilized by PYCR1-AS1)ROS/mitophagy markers in cancer tissue
Beyond the preview
Go deeper on PYCR1 antisense RNA 1 (PYCR1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PYCR1 antisense RNA 1 (PYCR1-AS1).